Chemoimmunotherapy as a new standard of care for Burkitt leukaemia/lymphoma
Mené en France sur 260 patients atteints d'un lymphome de Burkitt, cet essai multicentrique randomisé de phase III évalue l'efficacité, du point de vue de la survie sans événement à 3 ans, et la toxicité de l'ajout du rituximab à une chimiothérapie intensive de courte durée
Treatments targeting either specific transcripts (eg, breakpoint cluster region protein-Abelson murine leukaemia viral oncogene homologue 1 tyrosine kinase oncoprotein [BCR-ABL1] targeted by tyrosine kinase inhibitors) or leukaemic cell surface antigens (eg, CD20 monoclonal antibodies [mAbs]) could be major breakthroughs in the treatment of acute lymphoblastic leukaemia. Rituximab is a chimeric human–mouse mAb against CD20, with efficacy in several lymphoid malignancies. Assessment of the addition of rituximab to chemotherapy for acute lymphoblastic leukaemia has been based on positive data in high-grade non-Hodgkin lymphoma, which has shown that addition of rituximab to CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone or prednisolone) chemotherapy (R-CHOP) improves overall survival by at least 20%.